Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008 Jun;51(6):1403-1419.
Uncontrolled and apparent treatment resistant hypertension in the U.S. 1988 to 2008. Circulation 2011 Aug;124(9):1046-1058.
Closing the gap in hypertension control between younger and older adults: NHANES 1988 to 2010. Circulation 2014 May;129(20):2052-2061.
Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation 2014 Nov;30(19):1692-1699.
Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985 Mar;75(3):809-817.
World population prospects: the 2015 revision. New York: United Nations; 2015.
Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014 Aug;384(9945):766-781.
Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004 May;27(5):1047-1053.
Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011 May;57(5):898-902.
Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008 Nov;168(21):2340-2346.
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005 Nov;18(11):1422-1428.
Commentary on the sixth report of the Joint National Committee (JNC-6). Am J Hypertens 1998 Jan;11(1 Pt 1):134-136.
Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. Hypertension 2005 Jan;45(1):142-161.
Automated office blood pressure measurement in primary care. Can Fam Physician 2014 Feb;60(2):127-132.
Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol 2017 May;33(5):557-576.
Prevalence of optimal treatment regimens in patients with apparent treatment resistant hypertension in a community-based practice network. Hypertension 2013 Oct;62(4):691-697.
Screening for non-compliance among patients with hypertension: is self-report the best available measure? Med Care 1981 Oct;19(10):1061-1064.
Medication adherence: its importance in cardiovascular outcomes. Circulation 2009 Jun;119(23):3028-3035.
Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med 2011 Jul;171(13):1173-1180.
The effect of self-monitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. Am J Hypertens 2015 Oct;28(10):1209-1221.
Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006 May;47(5):846-853.
Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens 2014 Jun;8(6):405-413.
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertension 2014 Mar;32(3):635-643.
Prevalence, predictors and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med 2014 Jan;127(1):71.e1-81.e1.
Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment resistant hypertension. J Clin Hypertens (Greenwich) 2016 Aug;18(8):827-824.
Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 Apr;49(4):839-845.
; Hall, JE. Textbook of medical physiology. 11th ed. Philadelphia (PA): Elsevier; 2005.
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009 Sep;39(5):418-424.
Combination calcium channel blocker therapy in the treatment of hypertension. J Clin Hypertens 2001 Sep-Oct;3(5):322-327.
Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Lesson XVI: how to choose the correct drug for each hypertensive patient using a plasma renin-based method and the volume-vasoconstriction analysis. Am J Hypertens 2001 Jun;14(6):491-503.
Am J Hypertens 2009 Jul;22(7):792-801.
Management of the hypertensive patients with elevated heart rate: statement of the Second Consensus Conference endorsed by the European Society of Hypertension. J Hypertens 2016 May;34(5):813-821.
Blood Pressure and cholesterol control in hypertensive hypercholesterolemic patients: a report from NHANES 1988—2010. Circulation 2013 Jul;128(1):29-41.
2013 ACC/AHA cholesterol guideline and implications for healthy people 2020 Cardiovascular Disease Prevention Goals. J Am Heart Assoc 2016 Aug;5:e003558.
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011 Oct;29(10):2004-2013.
Seventh report of the Joint National Committee on Prevention, Detection, evaluation, and treatment of high blood pressure. Hypertension 2003 Dec;42(6):1206-1252.
